Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
136-482-Hyaluronoglucosaminidase PH20 (rHuPH20)[1] Hyaluronidase[3] D04455 ,
D04456 ,
D06604 		--[1] 65
2Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20)[3] Daratumumab,
Hyaluronidase,
Hyaluronidase (human recombinant)		[4] D04455 ,
D04456 ,
D06604 ,
D10777 		[1] CD38 💬[7] Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[1] 28
3Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20)[1] Daratumumab[1] D10777 [1] CD38 💬[7] Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[1] 28
4Recombinant Human Hyaluronidase (rHuPH20)[1] Hyaluronidase (human recombinant)---[1] 65
5Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)[1] Hyaluronidase (human recombinant)---[1] 65
6RHuPH20----[2] 13, 14
7SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----[1] 65
8SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----[1] 65